• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Microbiome Times

Finance

Metagen Therapeutics Completes Series A Financing Raising a Total of 1.7 Billion Yen

June 19, 2023 Microbiome Times

Metagen Therapeutics, a company focusing on drug discovery and development based on intestinal microbiome-based therapeutics for various diseases, has completed its Series A funding in 2 rounds, raising a total of 1.7 billion yen. Sparx […]

Finance

Verb Biotics announces acquisition of YSOPIA Bioscience health and wellness strains

June 14, 2023 Microbiome Times

Verb Biotics LLC., a microbiome innovation company, today announced that they have acquired YSOPIA Bioscience’s strain and IP portfolio targeted for human health and wellness. The acquisition of YSOPIA’s strain portfolio includes one of the […]

Pharma & Human Health

Scientists and clinicians use AI analysis of the gut microbiome to detect colon cancer

June 12, 2023 Microbiome Times

APC Microbiome Ireland, a world-leading SFI research centre based at UCC (University College Cork), has joined forces with BowelScreen and the Mater Misericordiae University Hospital, as part of 8 partner organisations from 5 European countries […]

Finance

Biocodex fully acquires TargEDys

June 6, 2023 Microbiome Times

TargEDys and Biocodex have been partners since 2019, when Biocodex became a shareholder and board member of TargEDys. Soon after, Biocodex became the distributor of TargEDys’ leading PreciBiomic, Symbiosys Satylia®, in France, then in Portugal […]

Finance

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability Of Vowst™

June 5, 2023 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced that VOWST™ (fecal microbiota spores, live-brpk) is now commercially available for patients. VOWST, formerly called SER-109, is the first and only U.S. Food and Drug […]

Pharma & Human Health

Ilya Pharma’s genetically modified lactic acid bacteria drug candidate effectively accelerates wound healing in clinical study

June 1, 2023 Microbiome Times

Complicated, hard-to-heal wounds are a growing medical problem and there are currently only two drugs approved with proven efficacy. In a new study on humans, researchers at Uppsala University show that treatment with a specific […]

Finance

BiomeSense Closes Oversubscribed $3 Million Funding Round

May 22, 2023 Microbiome Times

BiomeSense, a biotech company unlocking the vast health benefits of the microbiome through novel “smart bathroom” hardware technology and advanced bioinformatics, announced the close of its oversubscribed $3 million funding round. Led by Bluestein Ventures, the financing […]

Pharma & Human Health

NIH launches largest precision nutrition research effort of its kind

May 19, 2023 Microbiome Times

The National Institutes of Health is now enrolling participants in a landmark initiative to advance nutrition research. Nutrition for Precision Health, powered by the All of Us Research Program, or NPH, is working with 14 […]

Pharma & Human Health

Cerebiome® exerts a positive influence on the gut microbiota of individuals with mild anxiety, new study finds

May 17, 2023 Microbiome Times

Apsen Farmaceutica, Lallemand Health Solutions’ commercial partner in Brazil, is publishing new positive results on the influence of Cerebiome® on the gut microbiota of individuals with mild anxiety. The positive influence of Cerebiome® on the gut microbiota […]

Finance

Solarea Bio Announces First Close of Series B Financing Round

May 9, 2023 Microbiome Times

Solarea Bio, a clinical stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to aid human health, announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of […]

Finance

SNIPR Biome’s data on drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

May 8, 2023 Microbiome Times

SNIPR Biome ApS (“SNIPR”), the company pioneering CRISPR-based microbial gene therapy, announces that Nature Biotechnology has published research findings from its preclinical work on SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and […]

Posts navigation

« 1 … 14 15 16 … 76 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
sign up

Sign up to the Microbiome Times newsletter